By Stephen Nakrosis
Shares of Minerva Neurosciences Inc. soared nearly 73% to $7.81 per share on Wednesday.
After the bell Tuesday, billionaire hedge fund manager Steven Cohen's Point72 Asset Management L.P. disclosed that it has an 8.8% stake in the company.
On Monday, the Minerva's stock closed with a 47.83% gain after it submitted a new drug application with the U.S. Food and Drug Administration for roluperidone as a treatment for patients with schizophrenia.
Write to Stephen Nakrosis at email@example.com
(END) Dow Jones Newswires